Covalon Announces Second Quarter 2016 Earnings Conference Call

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, has scheduled a conference call to discuss its Q2 fiscal 2016 financial results.

The call will be held May 31, 2016 at 9 a.m. EST. To participate in the call please dial:

Local / International: 416-640-5946North American Toll- Free: 1 866-233-4585

Copies of Covalon’s financial statements, MD&A and additional information on Covalon Technologies Ltd. can be obtained on SEDAR at www.sedar.com, as well as the Company’s website at www.covalon.com.

About CovalonCovalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160526005257/en/

Covalon Technologies Ltd.
Brian Pedlar, 905.568.8400 x 233
CEO
[email protected]
Toll free: 1-877-711-6055
Web site: www.covalon.com
Twitter: @covalon

Source: Covalon Technologies Ltd.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Trustmark Corp (TRMK) Tops Q1 EPS by 7c
• IDEX Corp. (IEX) Tops Q1 EPS by 13c ; Offers Guidance